Jimin Health: On March 13, margin purchases of 4.505.3 million yuan, with margin financing and securities lending balance of 176 million yuan.

NightAirdropper · 2026-03-16T09:04:53+00:00

Jimin Health (603222) on March 13 had margin financing purchases of 4.5053 million yuan, margin financing repayments of 4.2209 million yuan, net purchases of 0.2844 million yuan, and margin financing balance of 17.6 million yuan. For short selling, 2,100 shares were sold short, net short selling of 2,100 shares, with short selling balance of 9,000 shares. The margin financing and short selling balance increased by 0.17%.

NightAirdropper

2026-03-16 09:04:53

Abstract generation in progress

Securities Star News: On March 13, Jiming Health (603222) had a margin buy of 4.5053 million yuan, a margin repayment of 4.2209 million yuan, with a net margin purchase of 284,400 yuan. The margin balance was 176 million yuan.

Regarding securities lending, on that day, 2,100 shares were sold short, with no shares repaid, resulting in a net short sale of 2,100 shares. The remaining securities lending balance was 9,000 shares.

The total margin and securities lending balance was 176 million yuan, up 0.17% from yesterday.

Quick Fact

Margin Trading and Securities Lending: Margin trading means a securities company lends money to investors to buy stocks. When the loan matures, the principal and interest are repaid together. Securities lending can be understood as investors borrowing stocks to sell; at maturity, they return the stocks and pay interest. Generally, investors buy stocks on margin if they are optimistic about the stock price, and sell short if they are bearish.

The above content is compiled from public information by Securities Star, generated by AI algorithm (Wangxin Calculation Backup No. 310104345710301240019), and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.